Hugo R Lara-Martinez: Recognizing HLH After Immune Checkpoint Inhibitor Therapy
Hugo R Lara-Martinez, Former Assistant Professor of Medicine- Hematology at MD Anderson Cancer Center, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Immunotherapy, adding:
”Excited to share our recently published case series on immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis (HLH).
We highlight the varied clinical presentations, diagnostic challenges, and treatment approaches in this rare but potentially life-threatening hematologic immune-related adverse event.
Grateful to my co-authors for their collaboration.”
Title: Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients
Authors: Mayte G. Martinez-Garza, Effrosyni Apostolidou, Hugo R. Lara-Martinez, Thein H. Oo, Cristhiam M. Rojas-Hernandez
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 1, 2026, 16:50Heghine Khachatryan: When to Test for Thrombophilia After VTE
-
Sep 1, 2026, 16:41Axel Diederichsen: Can Vitamin K2 and Vitamin D3 Slow the Progression of Severe Coronary Artery Calcification?
-
Sep 1, 2026, 16:15Sangeeta Pathak: The Bombay Blood Group as a Very Rare Phenotype
-
Sep 1, 2026, 16:14The Ecuador 2026 National Conference on Coagulation Disorders – WFH
-
Sep 1, 2026, 15:54Alejandro González Veliz: Can Treating Tricuspid Regurgitation Change Outcomes?
-
Sep 1, 2026, 15:51Ingo Ahrens: Another Step Forward in Catheter-Directed Thrombolysis for Acute PE
-
Sep 1, 2026, 15:20Sohail Khan: What Comes After IV Thrombolysis
-
Sep 1, 2026, 15:09Harish Chowdary Gorrepati: The HALT Paradox After TAV
-
Sep 1, 2026, 14:53Josef Kroupa: Landmark PRAGUE-26 Trial Advances Interventional PE Treatment